文献速递淋巴瘤造血干细胞移植与细胞治疗

阻断T细胞CD7表达以实现对T细胞恶性肿瘤的有效嵌合抗原受体靶向

Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies.
PubMed 文献 · Blood Adv · 2017-11-21

研究针对缺乏有效免疫治疗的T细胞恶性肿瘤,选择CD7为靶点,因CD7在T-ALL(含ETP-ALL)中一致性高表达。采用抗CD7-41BB-CD3ζ CAR时,T细胞自身CD7导致 fratricide(自相残杀)。应用蛋白质表达阻滞剂(PEBL)阻断CD7表面表达后,CAR T细胞体外和体内均显示强抗白血病活性,且与现有临床级细胞制造流程兼容。

要点

  • 49例诊断T-ALL样本(含14例ETP-ALL)中CD7中位表达>99%,复发和化疗期间仍高表达。
  • PEBL转导使所有转导T细胞表面CD7表达近乎即时消除,CD7+细胞为2.0%±1.7% vs 模拟转导的98.1%±1.5%(n=5;P<.0001)。
  • PEBL-CAR T细胞体外对CD7+白血病细胞高度细胞毒,且在细胞系和患者来源T-ALL异种移植中显示强抗白血病活性。

核心结论

  • 阻断CD7表达的PEBL策略可消除CAR介导的fratricide,使CD7 CAR T细胞有效靶向T细胞恶性肿瘤,并可与现有临床级细胞制造流程结合快速实施。

研究设计与样本

  • 研究采用抗CD7-41BB-CD3ζ二代CAR,并应用基于抗CD7单链可变区片段与细胞内滞留域偶联的蛋白质表达阻滞剂(PEBL)下调CD7。
  • 检测49例诊断T-ALL样本(包括14例ETP-ALL)、14例复发样本和54例化疗期间样本的CD7表达。
  • 在体外和细胞系及患者来源T-ALL异种移植模型中评估PEBL-CAR T细胞的功能。

主要发现

  • 49例诊断T-ALL样本(含14例ETP-ALL)中CD7中位表达>99%,复发时(n=14)和化疗期间(n=54)CD7表达仍高。
  • PEBL转导后所有转导T细胞表面CD7表达近乎即时消除,CD7+细胞为2.0%±1.7% vs 模拟转导T细胞的98.1%±1.5%(n=5;P<.0001)。
  • PEBL表达未损害T细胞增殖、干扰素-γ和肿瘤坏死因子-α分泌或细胞毒性,并消除了CAR介导的fratricide。
  • PEBL-CAR T细胞体外对CD7+白血病细胞高度细胞毒,且一致强于因fratricide而幸存的CD7+ T细胞。
  • PEBL-CAR T细胞在细胞系和患者来源T-ALL异种移植中显示强抗白血病活性。

临床怎么用

  • 作者认为该策略与现有临床级细胞制造流程契合良好,可快速用于治疗高风险T细胞恶性肿瘤患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Effective immunotherapies for T-cell malignancies are lacking. We devised a novel approach based on chimeric antigen receptor (CAR)-redirected T lymphocytes. We selected CD7 as a target because of its consistent expression in T-cell acute lymphoblastic leukemia (T-ALL), including the most aggressive subtype, early T-cell precursor (ETP)-ALL. In 49 diagnostic T-ALL samples (including 14 ETP-ALL samples), median CD7 expression was >99%; CD7 expression remained high at relapse (n = 14), and during chemotherapy (n = 54). We targeted CD7 with a second-generation CAR (anti-CD7-41BB-CD3ζ), but CAR expression in T lymphocytes caused fratricide due to the presence of CD7 in the T cells themselves. To downregulate CD7 and control fratricide, we applied a new method (protein expression blocker [PEBL]), based on an anti-CD7 single-chain variable fragment coupled with an intracellular retention domain. Transduction of anti-CD7 PEBL resulted in virtually instantaneous abrogation of surface CD7 expression in all transduced T cells; 2.0% ± 1.7% were CD7+ vs 98.1% ± 1.5% of mock-transduced T cells (n = 5; P < .0001). PEBL expression did not impair T-cell proliferation, interferon-γ and tumor necrosis factor-α secretion, or cytotoxicity, and eliminated CAR-mediated fratricide. PEBL-CAR T cells were highly cytotoxic against CD7+ leukemic cells in vitro and were consistently more potent than CD7+ T cells spared by fratricide. They also showed strong anti-leukemic activity in cell line- and patient-derived T-ALL xenografts. The strategy described in this study fits well with existing clinical-grade cell manufacturing processes and can be rapidly implemented for the treatment of patients with high-risk T-cell malignancies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Png YT, Vinanica N, Kamiya T, et al. Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies. Blood Adv. 2017. PMID: 29296885. doi:10.1182/bloodadvances.2017009928

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。